IGC Acquires Exclusive Rights For A Potential Alzheimer's Drug Development Candidate

One of subsidiaries of India Globalization Capital, Inc. (NYSE: IGC) reached an intellectual property license agreement for a potential Alzheimer’s drug development candidate.

Researchers at the Jawaharlal Nehru Center for Advanced Scientific (“JNCASR”), in India, conducted about 10 years of and discovery work on NMI (naphthalene monoimide) compounds and the role of NMI compounds on neurotoxicity associated with Alzheimer’s. Neurotoxicity, which can result from exposure to natural or synthetic substances, causes damage to the brain and the nervous system. In Alzheimer’s patients, neurotoxicity is linked to beta amyloid (Aβ) plaques and neuro fibrillary tangles.

JNCASR’s based on Alzheimer’s cell lines, identified one lead …

Full story available on Benzinga.com

More IGC Acquires Exclusive Rights For A Potential Alzheimer's Drug Development Candidate